Anti-SLC6A2 (NET) (Human) pAb

Contact us
MBL
Product Code: MBL-BMP029
Product Group: Primary Antibodies
Supplier: MBL
CodeSizePrice
MBL-BMP02950 ul£340.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
  • Flow Cytometry
  • Immunocytochemistry (ICC)
  • Immunohistochemistry (IHC)
  • Western Blot (WB)
Shipping:
4°C
Storage:
-20°C

Images

1 / 8
2 / 8
3 / 8
4 / 8
5 / 8
6 / 8
7 / 8
8 / 8
❮❯

Documents

Further Information

Applications:
WB - 1:1000 (chemiluminescence detection system) FCM - 1:200 ICC - 1:200 IHC - 1:1000 (Heat treatment required for paraffin)
Background:
SLC6A2, also known as NET, is a norepinephrine (noradrenaline) transporter, which regulates norepinephrine homeostasis by reuptaking the norepinephrine released into synaptic cleft in Na + - and Cl - - dependent manner. Mutation of the SLC6A2 gene can cause orthostatic intolerance, which is characterized by lightheadedness, fatigue, altered mental condition, and syncope. Drugs inhibiting the norepinephrine transporter such as antidepressants, cocaine, and amphetamines also lead to symptoms like orthostatic intolerance.
Formulation:
50 ul volume of PBS containing50% glycerol, pH 7.2. No preservative is contained.
Gene IDs:
Human: 6530 Mouse: 20538
Immunogen Translated:
Synthetic peptide derived from human SLC6A2
Reactivity:
This antibody can be used to stain endogenous antigen in paraffin embedded human tissues including the brain and liver by Immunohistochemistry. The reactivity has been confirmed by Western blotting, Immunocytochemistry, and intr acellular Flow cytometry to detect the full length of human SLC6A2 transiently expressed in HEK 293T cells.
Shelf Life:
1 year
Source:
This antibody was affinity purified from rabbit serum. The rabbit was immunized with a synthetic peptide derived from human SLC6A2.
Target:
SLC6A2/NET

References

?1) Kim, C. H., et al., PNAS 103, 19164-19169 (2006) 2) Paczkowski, F. A. et al., Pharmacogenetics 12, 165-173 (2002) 3) Shannon, J. R., et al., New Eng. J. Med. 342, 541-549 (2000) 4) Pacholczyk, T., et al., Nature 350, 350-354 (1991)